LDN193189 (Synonyms: DM-3189)

Name: LDN193189
Brand: MedChemExpress
SKU: HY-12071
Rating: 5.0 (83 reviews)

Cat. No.: HY-12071 Purity: 99.72%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

LDN193189 (DM-3189) is a potent selective BMP type I receptor (BMP I) inhibitor. LDN193189 efficiently inhibits transcriptional activity of the BMP type I receptors ALK2 and ALK3 with IC₅₀ values of 5 nM and 30 nM, respectively. LDN193189 can be used for the research of bone morphogenetic protein signalling, such as fibrodysplasia ossificans progressiva.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

CAS No. : 1062368-24-4

사이즈	재고	수량
2 mg	해외재고보유	Estimated Time of Arrival: December 31
5 mg	해외재고보유	Estimated Time of Arrival: December 31
10 mg	해외재고보유	Estimated Time of Arrival: December 31
25 mg	해외재고보유	Estimated Time of Arrival: December 31
50 mg	해외재고보유	Estimated Time of Arrival: December 31
100 mg	해외재고보유	Estimated Time of Arrival: December 31
200 mg	견적 받기
500 mg	견적 받기

or 대량구매 문의

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

This product is a controlled substance and not for sale in your territory.

고객리뷰

Based on 83 publication(s) in Google Scholar

Other Forms of LDN193189:

83 Publications Citing Use of MCE LDN193189

2D/3D Cell Culture and Differentiation

Cell Migration/Invasion Assay

IHC

: LDN193189 purchased from MedChemExpress. Usage Cited in: Sci Adv. 2025 Nov 28;11(48):eady7682. [Abstract]; The bar chart displayed the weighted average of day 13 budoid proportions exhibiting no elongation, elongation (short), or elongation (long) after treatment with LDN193189 Tetrahydrochloride (1-4 μM).

: LDN193189 purchased from MedChemExpress. Usage Cited in: Sci Adv. 2025 Nov 28;11(48):eady7682. [Abstract]; Max-projection confocal images of day 13 budoids were treated with LDN193189 Tetrahydrochloride (LDN) (1 μM). Gray: Hoechst; magenta: SOX9.

: LDN193189 purchased from MedChemExpress. Usage Cited in: Stem Cell Res Ther. 2022 Aug 19;13(1):424. [Abstract]; Phospho-Smad1/5/9, COL1A1 and RUNX2 were quantified in hBM-MSCs after 3 days of treatment with LDN193189 (100 nM; 3 days) by western blot analysis and normalized to GAPDH and tSmad1.

: LDN193189 purchased from MedChemExpress. Usage Cited in: Stem Cell Res Ther. 2022 Aug 19;13(1):424. [Abstract]; LDN193189 (100 nM; 3 days). Representative images and quantification of immunofluorescence staining of COL1A1. Scale bars, 100 μm.

: LDN193189 purchased from MedChemExpress. Usage Cited in: Stem Cell Res Ther. 2022 Aug 19;13(1):424. [Abstract]; LDN193189 (100 nM; 3 days). Representative images of ARS.

: LDN193189 purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2020 Jan 28;469:390-398. [Abstract]; LDN193189 Tetrahydrochloride (0.2–0.3 μM; 24 h) blocked Smad1/5/9 phosphorylation in KYSE30 and KYSE150 cells.

: LDN193189 purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2020 Jan 28;469:390-398. [Abstract]; LDN193189 Tetrahydrochloride (LDN) (0.2–0.3 μM; 24 h) inhibited the migration of KYSE30 and KYSE150 cells.

: LDN193189 purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2020 Jan 28;469:390-398. [Abstract]; Transwell assays were performed on SERPINE2-overexpressing KYSE30 and KYSE150 cells treated with or without LDN193189 Tetrahydrochloride (0.2–0.3 μM; 24 h) (LDN) in the lower chamber.

: LDN193189 purchased from MedChemExpress. Usage Cited in: Oxid Med Cell Longev. 2020 Jun 8;2020:4175613. [Abstract]; Western blot and grey analysis of CYP11a1, CYP19a1, BCL2, CALR, CHOP, caspase3, caspase12, PERK, and GRP78. qRT-PCR analyzed ATF4, caspase3, and GRP78 mRNAs. The relieving function of BMP4 on ER stress is diminished after blockade of BMP receptor I (BMPRI) with DM-3189.

: LDN193189 purchased from MedChemExpress. Usage Cited in: Cardiovasc Toxicol. 2019 Jun;19(3):264-275. [Abstract]; H9c2 cells are treated as following: control, DOX, DOX + rhBMP (Bmpr1a agonist) and DOX + LDN193189 (Bmpr1a inhibitor). Cells with red fluorescence indicate favorable MMP while green fluorescence indicates damage.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All TGF-β Receptor Isoform Specific Products:

View All Isoforms

ALK1 ALK2 ALK3 ALK4 ALK5 ALK6 ALK7 TGFβR2 ACVR2A ACVR2B BMP GDF15

Biological Activity
순도&문서
References
고객리뷰

제품 설명

IC₅₀ & Target^[1]

ACVR1

5 nM (IC₅₀)

BMPR1A

30 nM (IC₅₀)

In Vitro

LDN193189 efficiently inhibits transcriptional activity of the BMP type I receptors ALK2 and ALK3 with IC₅₀ values of 5 nM and 30 nM, respectively^[1].
LDN193189 has weake effects on activin and the TGF-β type I receptors ALK4, ALK5 and ALK7 with IC₅₀ values of ≥ 500 nM^[1].
LDN193189 binds ActRIIA with K_d value of 14 nM^[2].
LDN193189 (0.5 μM; 30 min) targets GDF8 induced Smad2/3 signaling and repression of myogenic transcription factors^[2].
LDN193189 (0.05, 0.5, 5 μM) efficiently inhibits GDF8 induced Smad3/4 reporter gene activity^[2].
LDN193189 (0-5 μM) rescues myogenesis in myoblasts treated with GDF8^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[2]

Cell Line:	Primary human myoblasts, C2C12 cells
Concentration:	0.5 μM
Incubation Time:	30 min
Result:	Inhibited GDF8-induced signaling pathways in undifferentiated and in differentiated primary human myoblasts and in C2C12 premyoblasts.

In Vivo

LDN193189 (i.p.; 3 mg/kg; daily; for 35 days) might affect the interaction between breast cancer cells and the bone environment^[3].
LDN193189 (i.p.; 3 mg/kg; single) shows a reduction in ectopic ossification and functional impairment^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Ahymic NMRI nude female mice (6-week-old)^[3]
Dosage:	3 mg/kg
Administration:	Itraperitoneal, daily, for 35 days
Result:	Ehanced etastases development in vivo.

Animal Model:	C57BL/6 mice^[1]
Dosage:	3 mg/kg
Administration:	Intraperitoneal, single
Result:	Diminished ectopic bone formation and preserved joint spaces over the same interval without inducing fractures, osteopenia or skeletal abnormalities.

분자량

406.49

화학식

C₂₅H₂₂N₆

CAS No.

1062368-24-4

Appearance

Solid

Color

Light yellow to yellow

SMILES

C1(C2=C3N=CC(C4=CC=C(N5CCNCC5)C=C4)=CN3N=C2)=CC=NC6=CC=CC=C16

선적

Room temperature in continental US; may vary elsewhere.

보관

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

용액&용해도

In Vitro:

DMSO : 12.5 mg/mL (30.75 mM; ultrasonic and adjust pH to 4 with HCl; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : 5 mg/mL (12.30 mM; ultrasonic and warming and adjust pH to 2 with 1 M HCL and heat to 60°C)

H₂O : < 0.1 mg/mL (insoluble)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.4601 mL	12.3004 mL	24.6009 mL
5 mM	0.4920 mL	2.4601 mL	4.9202 mL
10 mM	0.2460 mL	1.2300 mL	2.4601 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

몰농도 계산기
농도 희석 계산기

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 1 mg/mL (2.46 mM); Clear solution; Need ultrasonic

This protocol yields a clear solution of 1 mg/mL.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 1 mg/mL (2.46 mM); Clear solution; Need ultrasonic

This protocol yields a clear solution of 1 mg/mL.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

순도&문서

Purity: 99.72%

Select Batch:

Data Sheet (282 KB) SDS (251 KB)

COA (254 KB) HNMR (289 KB) RP-HPLC (226 KB) MS (70 KB)

Handling Instructions (2659 KB)

References

[1]. Yu PB, et al. BMP type I receptor inhibition reduces heterotopic [corrected] ossification. Nat Med, 2008, 14(12), 1363-1369. [Content Brief]

[2]. Daniel Horbelt, et al. Small molecules dorsomorphin and LDN-193189 inhibit myostatin/GDF8 signaling and promote functional myoblast differentiation. J Biol Chem. 2015 Feb 6;290(6):3390-404. [Content Brief]

[3]. Julien Vollaire, et al. The Bone Morphogenetic Protein Signaling Inhibitor LDN-193189 Enhances Metastasis Development in Mice. Front Pharmacol. 2019 Jun 19;10:667. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

H₂O / DMSO	1 mM	2.4601 mL	12.3004 mL	24.6009 mL	61.5021 mL
	5 mM	0.4920 mL	2.4601 mL	4.9202 mL	12.3004 mL
	10 mM	0.2460 mL	1.2300 mL	2.4601 mL	6.1502 mL
DMSO	15 mM	0.1640 mL	0.8200 mL	1.6401 mL	4.1001 mL
	20 mM	0.1230 mL	0.6150 mL	1.2300 mL	3.0751 mL
	25 mM	0.0984 mL	0.4920 mL	0.9840 mL	2.4601 mL
	30 mM	0.0820 mL	0.4100 mL	0.8200 mL	2.0501 mL

LDN193189 Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

최근 본 상품:

상품명

Requested Quantity *

고객명 *

호칭

메일주소 *

전화번호 *

Department

회사명 *

City

도

Country or Region *

비고

상품명

Lot #

고객명 *

메일주소 *

전화번호

Department *

회사명 *

Country or Region *

비고

Name
이메일 *

	Sorry, but the email address you supplied was invalid.

LDN193189 (Synonyms: DM-3189)

고객리뷰

Other Forms of LDN193189:

LDN193189 Related Antibodies

83 Publications Citing Use of MCE LDN193189

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All TGF-β Receptor Isoform Specific Products:

Biological Activity

순도&문서

References

고객리뷰

LDN193189 Related Antibodies

몰농도 계산기

농도 희석 계산기

Complete Stock Solution Preparation Table

LDN193189 Related Classifications

Keywords:

최근 본 상품:

고객리뷰

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report